Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen

Seres Therapeutics (NASDAQ:MCRB) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $14.33.

Seres Therapeutics Trading Up 3.0%

MCRB stock opened at $8.47 on Friday. The firm has a 50 day moving average of $15.06 and a 200-day moving average of $16.77. Seres Therapeutics has a 12-month low of $6.53 and a 12-month high of $29.98. The company has a market cap of $76.65 million, a price-to-earnings ratio of -2.37 and a beta of 0.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Seres Therapeutics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 1,160 shares during the last quarter. Vanguard Group Inc. boosted its position in Seres Therapeutics by 6.8% during the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after acquiring an additional 19,793 shares during the last quarter. XTX Topco Ltd purchased a new stake in Seres Therapeutics in the 2nd quarter worth approximately $249,000. Vontobel Holding Ltd. raised its holdings in Seres Therapeutics by 22.6% in the 3rd quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company’s stock valued at $1,895,000 after acquiring an additional 18,186 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares during the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.